WHO and partners respond to the outbreak of Ebola virus disease in Guinea

Share it with your friends Like

Thanks! Share it with your friends!


This video produced in August 2014 looks at the response of WHO and partners to the outbreak of Ebola virus disease in Guinea and neighbouring countries.

Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%. It is one of the world’s most virulent diseases.The infection is transmitted by direct contact with the blood, body fluids and tissues of infected animals or people. Severely ill patients require intensive supportive care. During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients.

Ebola virus disease outbreaks can devastate families and communities, but the infection can be controlled through the use of recommended protective measures in clinics and hospitals, at community gatherings, or at home.

More information: http://www.who.int/csr/disease/ebola/en/


Zoila Villavicencio de Muck says:

Deseando el éxito en esta lucha contra esta terrible enfermedad.

William Liu says:

The process uses the byproduct of tobacco, and then cultivate it using human cancer cells. In other words, smokers can be used as host bodies also to produce antibodies similar to ZMAPP???? Has anyone tried blood transfusion from the surviving patients?

William Liu says:

ZMapp is manufactured in the tobacco plantNicotiana benthamiana in the bioproductionprocess known as "pharming" by Kentucky BioProcessing, a subsidiary of Reynolds American.[2][31] Monoclonal antibodies (mAbs) were first created in mice by injecting them with antigens from Ebola, harvesting their spleens, and fusing mature B-cellsproducing monoclonal antibodies (mAbs) with cancer cell lines to create hybridomas. After the best antibody is selected, the gene encoding the antibody was extracted, and certain portions were replaced with portions encoding human proteins, in the process called humanization. To create a system to produce the humanized mAbs at commercial scale, Mapp used a process called "Rapid Antibody Manufacturing Platform" (RAMP), using magnICON (ICON Genetics) viral vectors. In a process called "magnifection," tobacco plants are infected with the viruses, using Agrobacterium cultures.[2][28][32]Subsequently, antibodies are extracted and purified from the plants. Once the genes encoding the humanized mAbs are in hand, the entire tobacco production cycle is believed to take a few months.[9]

Write a comment